Cempra Inc  

(Public, NASDAQ:CEMP)   Watch this stock  
Find more results for CEMP
21.31
+0.80 (3.90%)
Dec 19 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 19.86 - 21.45
52 week 8.10 - 21.45
Open 21.00
Vol / Avg. 1.23M/489,833.00
Mkt cap 763.70M
P/E     -
Div/yield     -
EPS -1.85
Shares 35.84M
Beta     -
Inst. own 76%
Feb 25, 2015
Q4 2014 Cempra Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Dec 16, 2014
Cempra Inc at Guggenheim Healthcare Day - Life Sciences
Dec 10, 2014
Cempra Inc at Oppenheimer Healthcare Conference
Nov 19, 2014
Cempra Inc at Jefferies Global Healthcare Conference - London
Nov 18, 2014
Cempra Inc at Stifel Healthcare Conference
Nov 4, 2014
Cempra Inc at EBD Group BIO-Europe Conference
Oct 29, 2014
Q3 2014 Cempra Inc Earnings Call
Oct 29, 2014
Q3 2014 Cempra Inc Earnings Release
Sep 26, 2014
Cempra Inc at BioCentury Publications NewsMakers in the Biotech Industry
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -146.22% -576.41%
Operating margin -138.29% -549.35%
EBITD margin - -548.84%
Return on average assets -58.61% -53.06%
Return on average equity -116.83% -70.51%
Employees 38 -
CDP Score - -

Address

6320 Quadrangle Dr Ste 360
CHAPEL HILL, NC 27517-7890
United States - Map
+1-919-5762306 (Phone)
+1-302-5313150 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Cempra, Inc., formerly Cempra Holdings, LLC, is a development-stage and clinical-stage pharmaceutical company focused on developing antibiotics to meet medical needs in the treatment of bacterial infectious diseases, particularly respiratory tract infections and chronic and acute staphylococcal infections. Its program CEM-101 is developing in both oral and intravenous (IV), formulations initially for the treatment of community-acquired bacterial pneumonia (CABP). Its second program is Taksta, which is developing in the United States as an oral treatment for bacterial infections caused by Staphylococcus aureus (S. Aureus), including methicillin-resistant S. aureus (MRSA). As of January 30, 2012, the Company completed a Phase II clinical trial in, which the oral formulation of CEM-101 demonstrated comparable efficacy to the levofloxacin. As of January 30, 2012, its second program Taksta has completed a Phase II clinical trial in patients.

Officers and directors

Garheng Kong M.D. Ph.D. Independent Chairman of the Board
Age: 39
Bio & Compensation  - Reuters
Prabhavathi B. Fernandes Ph.D. President, Chief Executive Officer, Director
Age: 64
Bio & Compensation  - Reuters
Mark M. Hahn Chief Financial Officer, Executive Vice President
Age: 51
Bio & Compensation  - Reuters
David S. Moore Executive Vice President, Chief Commercial Officer
Bio & Compensation  - Reuters
Michael R. Dougherty Independent Director
Age: 56
Bio & Compensation  - Reuters
David N. Gill Independent Director
Age: 59
Bio & Compensation  - Reuters
Dov A. Goldstein M.D. Independent Director
Age: 45
Bio & Compensation  - Reuters
John H. Johnson Independent Director
Age: 56
Bio & Compensation  - Reuters
Richard S. Kent M.D. Independent Director
Age: 64
Bio & Compensation  - Reuters